Posts Tagged ‘Avenova’

NovaBay Pharmaceuticals Announces Investments of $5 Million to Support U.S. Avenova Commercialization Strategy

EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces investments totaling $5 million to support the recent strategic shift in its U.S. commercialization strategy aimed at driving growth in Avenova sales while maintaining cost effectiveness. The investments include a convertible loan of $2.0…

Read More